Iowa Senate Bill SF2322

Iowa 2025-2026 Regular Session

• Introduced: 2/12/26
• Refer: 2/12/26

Caption

A bill for an act relating to insurance coverage for prescription insulin drugs.

Impact

The enactment of SF2322 will significantly affect health insurance policies in Iowa, particularly those related to coverage for prescription medications. Starting from January 1, 2027, any contracts that include coverage for prescription drugs will be subject to the new cost-sharing cap. This change is expected to improve accessibility to insulin for those who depend on it, potentially reducing the incidence of uncontrolled diabetes due to financial barriers. This regulation aims to standardize cost-sharing for insulin across various insurance policies, promoting fairness in how patients are charged for essential diabetes management medications.

Summary

Senate File 2322 is a legislative proposal aimed at addressing the cost of prescription insulin drugs and improving health insurance coverage for individuals who require these medications for managing diabetes. The bill mandates that any third-party payment provider that delivers or renews health insurance policies in Iowa must limit the cost-sharing obligation for insulin prescriptions to a maximum of $35 for up to a 31-day supply. This provision is designed to alleviate the financial burden on diabetic patients who often face high out-of-pocket costs when purchasing insulin.

Contention

Despite its intent to provide economic relief, the bill is not without contention. Critics may argue that by capping cost-sharing at a set amount, it could lead insurers to alter their policies in a way that reduces the overall coverage or accessibility of other necessary medications. Moreover, opponents might voice concerns regarding how this legislation interacts with existing health care regulations and whether it could inadvertently create gaps in coverage for other chronic conditions alongside diabetes. There may also be worries about the implications of this law on the insurance market dynamics and the potential for premiums to rise as insurers adjust to comply with the new mandates.